Jonathan Jay Mazelsky - Feb 13, 2025 Form 4 Insider Report for IDEXX LABORATORIES INC /DE (IDXX)

Role
President and CEO, Director
Signature
/s/ Lily J. Lu, Attorney-in-Fact for Jonathan Jay Mazelsky
Stock symbol
IDXX
Transactions as of
Feb 13, 2025
Transactions value $
-$543,216
Form type
4
Date filed
2/18/2025, 09:43 PM
Previous filing
Jan 14, 2025
Next filing
Apr 2, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction IDXX Common Stock Options Exercise $0 +689 +0.84% $0.00 82.4K Feb 14, 2025 Direct F1
transaction IDXX Common Stock Options Exercise $0 +958 +1.16% $0.00 83.4K Feb 14, 2025 Direct
transaction IDXX Common Stock Options Exercise $0 +1.1K +1.32% $0.00 84.5K Feb 14, 2025 Direct
transaction IDXX Common Stock Tax liability -$543K -1.22K -1.45% $444.53 83.3K Feb 14, 2025 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IDXX Non-Qualified Stock Option (right-to-buy) Award $0 +25.9K $0.00 25.9K Feb 13, 2025 Common Stock 25.9K $459.76 Direct F2
transaction IDXX Incentive Stock Option (right-to-buy) Award $0 +217 $0.00 217 Feb 13, 2025 Common Stock 217 $459.76 Direct F3
transaction IDXX Restricted Stock Unit Options Exercise $0 -689 -100% $0.00 0 Feb 14, 2025 Common Stock 689 Direct F4
transaction IDXX Restricted Stock Unit Options Exercise $0 -958 -50% $0.00 958 Feb 14, 2025 Common Stock 958 Direct F5
transaction IDXX Restricted Stock Unit Options Exercise $0 -1.1K -33.35% $0.00 2.2K Feb 14, 2025 Common Stock 1.1K Direct F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes a total of 25 shares purchased under the Issuer's Employee Stock Purchase Plan on September 30, 2024 and December 31, 2024
F2 Grant of option to buy shares of Issuer common stock that becomes exercisable in four annual installments beginning February 14, 2026.
F3 Grant of option to buy shares of Issuer common stock that becomes exercisable in one installment on February 14, 2029.
F4 Each restricted stock unit ('RSU') represents a contingent right to receive one share of Issuer common stock. This RSU grant vested in four annual installments, beginning February 14, 2022.
F5 Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2023.
F6 Each RSU represents a contingent right to receive one share of Issuer common stock and vests in four annual installments, beginning February 14, 2024.